Trial Profile

1-yr Study Comparing TioSal Combo Regimens Versus Single Agent Therapies (Spiriva HandiHaler and Salmeterol PE Capsule)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 24 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Salmeterol/tiotropium bromide (Primary) ; Salmeterol; Tiotropium bromide
Indications Chronic obstructive pulmonary disease
Focus Registrational; Therapeutic Use
Sponsors Boehringer Ingelheim; Boehringer Ingelheim Pharmaceuticals

Most Recent Events

21 Jan 2022 This trial has been completed in Finland(End Date: 21 Nov 2008), according to European Clinical Trials Database record.
19 Jan 2022 This trial has been completed in Greece (End Date: 21 Nov 2008), according to European Clinical Trials Database record.
30 Sep 2021 This trial has been completed in France (End Date: 21 Nov 2008), according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com